Non‐IL ‐2‐blocking anti‐CD25 antibody inhibits tumor growth by depleting Tregs and has synergistic effects with anti‐CTLA ‐4 therapy
International Journal of Cancer · 2024-04 · 154 (7) · 1285-1297
DOI: 10.1002/ijc.34823 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 05.01.2024. Verfasst von Yujia Peng und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, S…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Science and Technology Plan Project of Sichuan Province (Provincial Academy and Provincial University Cooperation Project), Sichuan Science and Technology Program, Sichuan University start-up funding.
Abstract (Originalsprache)
CD25, also known as the interleukin‐2 receptor α chain (IL‐2Rα), is highly expressed on regulatory T cells (Tregs), but relatively lower on effector T cells (Teffs). This makes it a potential target for Treg depletion, which can be used in tumor immunotherapy. However, marketed anti‐CD25 antibodies (Basiliximab and Daclizumab) were originally developed as immunosuppressive drugs to prevent graft rejection, because these antibodies can block IL‐2 binding to CD25 on Teffs, which in turn destroys the function of Teffs. Recent studies have shown that non‐IL‐2‐blocking anti‐CD25 antibodies have displayed exciting antitumor effects. Here, we screened out a non‐IL‐2‐blocking anti‐CD25 monoclonal antibody (mAb) 7B7 by hybridoma technology, and confirmed its antitumor activity via depleting Tregs in a CD25 humanized mouse model. Subsequently, we verified that the humanized 7B7, named as h7B7‐15S, has comparable activities to 7B7, and that its Treg depletion is further increased when combined with anti‐CTLA‐4, leading to enhanced remodeling of the tumor immune microenvironment. Moreover, our findings reveal that the Fab form of h7B7‐15S has the ability to deplete Tregs, independent of the Fc region. Taken together, our studies expand the application of anti‐CD25 in tumor immunotherapy and provide insight into the underlying mechanism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
- Department of Head and Neck Oncology, West China Hospital, Sichuan University, Chengdu, China.
- Precision Medicine Key Laboratory of Sichuan Province & Precision Medicine Research Center, West China Hospital, Sichuan University, Chengdu, China.
- Research Unit of Gene and Immunotherapy, Chinese Academy of Medical Sciences, Chengdu, China.
ORCID-Profile: Jinliang Yang
Förderung
- Science and Technology Plan Project of Sichuan Province (Provincial Academy and Provincial University Cooperation Project)
- Sichuan Science and Technology Program
- Sichuan University start-up funding
- Ministry of Science and Technology of China (MoST)
- The National Major Scientific and Technological Special Project for Significant New Drugs Development
- The National Natural Science Foundation of China
- The CAMS Innovation Fund for Medical Sciences (CIFMS)
Zitieren
APA
Peng, Y., Fu, Y., Liu, H., Zhao, S., Deng, H., Jiang, X., Lai, Q., Lu, Y., Guo, C., Zhang, G., Luo, Y., Wang, Y., Gou, L., & Yang, J. (2024). Non‐IL ‐2‐blocking anti‐CD25 antibody inhibits tumor growth by depleting Tregs and has synergistic effects with anti‐CTLA ‐4 therapy. International Journal of Cancer, 154(7), 1285-1297. https://doi.org/10.1002/ijc.34823
Vancouver
Peng Y, Fu Y, Liu H, Zhao S, Deng H, Jiang X, et al. Non‐IL ‐2‐blocking anti‐CD25 antibody inhibits tumor growth by depleting Tregs and has synergistic effects with anti‐CTLA ‐4 therapy. International Journal of Cancer. 2024;154(7):1285-1297. doi:10.1002/ijc.34823
BibTeX
@article{Peng2024,
author = {Peng, Yujia and Fu, Yuyin and Liu, Hong and Zhao, Shengyan and Deng, Han and Jiang, Xiaohua and Lai, Qinhuai and Lu, Ying and Guo, Cuiyu and Zhang, Guangbing and Luo, Yong and Wang, Yuxi and Gou, Lantu and Yang, Jinliang},
title = {Non‐IL ‐2‐blocking anti‐CD25 antibody inhibits tumor growth by depleting Tregs and has synergistic effects with anti‐CTLA ‐4 therapy},
journal = {International Journal of Cancer},
year = {2024},
volume = {154},
number = {7},
pages = {1285--1297},
doi = {10.1002/ijc.34823}
}
EUVIMED